Eli Lilly: Quiet Momentum Builds Into Q3 Earnings, But Watch The Chart Too (NYSE:LLY)
· seekingalpha.com
Top and bottom line beats, with broad drug sales momentum, along with beefy gross margins, made Eli Lilly to raise FY 2026 guidance. Read why LLY stock is a Buy.
Eli Lilly ( LLY ) remains the stalwart Health Care sector stock. As the group broadly trades lower amid rising interest rates, LLY holds its own amid the GLP-1 ...